Research ExplorerPublicationsHealth-related quality of life outcomes from the CANDOR stud...

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

Standard

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. / Siegel, David; Weisel, Katja; Zahlten-Kumeli, Anita; Medhekar, Rohan; Ding, Bifeng; Leleu, Xavier.

In: LEUKEMIA LYMPHOMA, Vol. 62, No. 12, 12.2021, p. 3002-3010.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Siegel, D, Weisel, K, Zahlten-Kumeli, A, Medhekar, R, Ding, B & Leleu, X 2021, 'Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma', LEUKEMIA LYMPHOMA, vol. 62, no. 12, pp. 3002-3010. https://doi.org/10.1080/10428194.2021.1941927

APA

Siegel, D., Weisel, K., Zahlten-Kumeli, A., Medhekar, R., Ding, B., & Leleu, X. (2021). Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. LEUKEMIA LYMPHOMA, 62(12), 3002-3010. https://doi.org/10.1080/10428194.2021.1941927

Vancouver

Siegel D, Weisel K, Zahlten-Kumeli A, Medhekar R, Ding B, Leleu X. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. LEUKEMIA LYMPHOMA. 2021 Dec;62(12):3002-3010. https://doi.org/10.1080/10428194.2021.1941927

Bibtex

@article{a109e54f05944c1193169042f1a30083,
title = "Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma",
abstract = "CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality of life (HRQoL) scores using the Global Health Status (GHS)/Quality of Life (QoL) domain of the EORTC QLQ-C30. Scores were compared between KdD and Kd using a restricted maximum likelihood-based mixed effects model for repeated measures. GHS/QoL completion rates were >81% for both arms. Higher GHS/QoL scores were observed with KdD versus Kd from Cycle 7-26. The overall least squares mean estimate (95% CI) of the difference between treatment arms was 0.06 (-2.39 to 2.50; p = 0.96). In an exploratory analysis, 55.5% in the KdD arm and 43.0% in the Kd arm improved ≥10 points in GHS/QoL score from baseline. HRQoL was maintained with KdD, consistent with superior clinical benefit observed with KdD versus Kd in patients with RRMM.",
author = "David Siegel and Katja Weisel and Anita Zahlten-Kumeli and Rohan Medhekar and Bifeng Ding and Xavier Leleu",
year = "2021",
month = dec,
doi = "10.1080/10428194.2021.1941927",
language = "English",
volume = "62",
pages = "3002--3010",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "12",

}

RIS

TY - JOUR

T1 - Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

AU - Siegel, David

AU - Weisel, Katja

AU - Zahlten-Kumeli, Anita

AU - Medhekar, Rohan

AU - Ding, Bifeng

AU - Leleu, Xavier

PY - 2021/12

Y1 - 2021/12

N2 - CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality of life (HRQoL) scores using the Global Health Status (GHS)/Quality of Life (QoL) domain of the EORTC QLQ-C30. Scores were compared between KdD and Kd using a restricted maximum likelihood-based mixed effects model for repeated measures. GHS/QoL completion rates were >81% for both arms. Higher GHS/QoL scores were observed with KdD versus Kd from Cycle 7-26. The overall least squares mean estimate (95% CI) of the difference between treatment arms was 0.06 (-2.39 to 2.50; p = 0.96). In an exploratory analysis, 55.5% in the KdD arm and 43.0% in the Kd arm improved ≥10 points in GHS/QoL score from baseline. HRQoL was maintained with KdD, consistent with superior clinical benefit observed with KdD versus Kd in patients with RRMM.

AB - CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality of life (HRQoL) scores using the Global Health Status (GHS)/Quality of Life (QoL) domain of the EORTC QLQ-C30. Scores were compared between KdD and Kd using a restricted maximum likelihood-based mixed effects model for repeated measures. GHS/QoL completion rates were >81% for both arms. Higher GHS/QoL scores were observed with KdD versus Kd from Cycle 7-26. The overall least squares mean estimate (95% CI) of the difference between treatment arms was 0.06 (-2.39 to 2.50; p = 0.96). In an exploratory analysis, 55.5% in the KdD arm and 43.0% in the Kd arm improved ≥10 points in GHS/QoL score from baseline. HRQoL was maintained with KdD, consistent with superior clinical benefit observed with KdD versus Kd in patients with RRMM.

U2 - 10.1080/10428194.2021.1941927

DO - 10.1080/10428194.2021.1941927

M3 - SCORING: Journal article

C2 - 34180331

VL - 62

SP - 3002

EP - 3010

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 12

ER -